Gil Bashe MM&M - Medical Marketing and Media

Gil Bashe

Most recent articles by Gil Bashe

FTC ‘cure’ for reverse-payments worse than disease

By now, you’ve probably heard about FTC efforts to ban reverse-payment patent settlements. FTC chairman Jon Leibowitz claims pharma-generic company deals are among “the most corrupt practices in healthcare today,” asserting settlements prevent cheaper generic drugs from entering the market sooner, delaying savings to consumers.

Social Etiquette

Just as it followed other sectors into CRM, the pharma industry must find entry points into the online patient conversation. Gil Bashe explores some of the issues, hurdles and opportunities of Web 2.0

PR View by Gil Bashe

Treating rare disorders was once considered a “good-will science endeavor,” but market forces have encouraged companies to revisit how these small molecules can be big business, and researchers are finding that therapeutic applications for one rare disease area often holds promise in others.